Eye drops redefined

An eye for innovation in eye care

EYE-GO

Administering topical eye medication is a massive challenge for patients in particular for seniors and children, but also for all other age groups. This potentially results in poor treatment outcomes, low compliance, blindness and poor quality of life.

EYE-GO is an international development stage company, with focus on solving the above issues by use of innovative device technology

PATIENTS and casual users also experience DIFFICULTIES with the eye drop bottle

Difficult to aim / Difficult to squeeze / Overdosing – every time / Adverse events

DROP BOTTLE issues are key to LOW COMPLIANCE

 

 

icon-glaucoma-ading-blindess

Only 10% of glaucoma patients are treatment compliant

Approx. 120.000 Americans are blind from glaucoma

Non compliance causes blindness

We have a solution

 

 

Precise dosing through a mist technology

Precise delivery of the medication

Easy to handle device – even with low dexterity

Preservative free formulations

Range of viscosities

Increase compliance

News

EYE-GO Closes major investment round with existing investors and Maj Invest Holding, one of the most successful capital funds in Denmark.

EYE-GO partners up with DTU on Master Project in a virgin field of research within ophthalmology

2018/10 new CEO take over leadership of company. 20+ years of international management experience in world-leadning Life Science companies. Focused on bringing medical devices from idea to market in the fastest and most efficient way. Previous roles includes VP in Coloplast and Ambu

EYE-GO patents have been granted in US and Europe. New patents submitted and new, international customer in place

Strong team in medical devices

We work together as one team of people with expertise and determination to achieve our goals collectively. Our values of respect, trust, and appreciation are at the very core of our foundation.

Management

Henrik NagelCEO
hna@eye-go.com
M.: +45 9398 9339

Executive Board

Board Chairman
Christian Stig Moeller
GM Fisher Investments

Board member
Ole Feddersen

Novo Nordisk

Board member
Joachim Vanggaard
Maj Invest Holding

 

 

Advisory

Commercial
Bent Johnsen
Ex- Novo Nordisk, PNL

Development Engineering
Kurt Solgaard

DTU – Technical University of Denmark – Institute for Mechanical Engineering

Rigshospitalets Øjenafdeling (National Hospital of Denmark, Ophthalmic ward and research unit)